Talampanel

Talampanel
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (8R)-7-Acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine;
CAS Number	161832-65-1 ;
PubChem CID	164509;
ChemSpider	144217 ;
UNII	CVS43XG1L5;
ChEMBL	ChEMBL61872 ;
CompTox Dashboard (EPA)	DTXSID10167259 ;
ECHA InfoCard	100.230.001
Chemical and physical data
Formula	C19H19N3O3
Molar mass	337.379 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Nc4ccc(cc4)C(=NN2C(=O)C)c3cc1OCOc1cc3CC2C;
	InChI InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1 ; Key:JACAAXNEHGBPOQ-LLVKDONJSA-N ;
	(what is this?) (verify)

Talampanel (INN; development codes GYKI 537773 and LY300164) is a drug which has been investigated for the treatment of epilepsy,^[1]^[2] malignant gliomas,^[3] and amyotrophic lateral sclerosis (ALS).^[4]

ATC code

none

Legal status

Investigational

CAS Number

161832-65-1^N

PubChem CID

164509

Quick facts Clinical data, ATC code ...

Close

As of May 2010, results from the trial for ALS have been found negative.^[5] Talampanel is not currently under development.

Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of ionotropic glutamate receptor in the central nervous system.^[6]

It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.^[7]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Talampanel

See also

References

Related Articles